VLN Cigarettes: Reducing Harm and Nicotine Intake

VLN Cigarettes


In today’s world, where health consciousness is on the rise, reducing the harm caused by smoking is a pressing concern. One innovative solution that has gained significant attention is VLN® cigarettes, which offer a reduced nicotine content compared to conventional cigarettes. In this article, we will explore the benefits of VLN® cigarettes, their unique features, and the potential they hold for harm reduction and nicotine intake reduction.

Understanding VLN® Cigarettes

What are VLN® Cigarettes?

VLN® cigarettes, developed by 22nd Century Group, are the world’s first combustible cigarettes to receive Modified Risk Tobacco Product (MRTP) authorization from the U.S. Food and Drug Administration (FDA). These cigarettes contain 95% less nicotine than traditional cigarettes, making them a potential game-changer in reducing nicotine dependence.

The FDA’s Recognition

The FDA’s MRTP authorization acknowledges the significant impact of VLN® cigarettes in reducing exposure to and consumption of nicotine. This recognition paves the way for smokers who wish to reduce their nicotine intake without sacrificing the smoking experience they are accustomed to.

Key Features of VLN® Cigarettes

VLN® cigarettes offer several key features that set them apart from conventional cigarettes:

  1. Reduced Smoking Frequency and Duration: VLN® cigarettes have been shown to help reduce smoking frequency and duration, aiding smokers in their journey towards reduced nicotine consumption.
  2. Significantly Lower Nicotine Content: With 95% less nicotine, VLN® cigarettes provide smokers with an alternative that allows them to gradually reduce their nicotine intake.
  3. Effective Nicotine Consumption Reduction: VLN® cigarettes can greatly reduce nicotine consumption, making them an excellent choice for individuals looking to reduce their dependence on nicotine.

The Science Behind VLN® Cigarettes

VLN® cigarettes are made with 22nd Century Group’s specially developed tobacco, which contains only 0.5 mg of nicotine per gram of tobacco. This low nicotine content aligns with the FDA’s proposed rulemaking for minimally or non-addictive nicotine levels in combustible cigarettes.

For decades, “Big Tobacco” has intentionally manipulated nicotine levels in their products to create and sustain addiction. In contrast, 22nd Century Group collaborated with world-class scientists to develop VLN® cigarettes, which aim to do the exact opposite by providing a reduced nicotine alternative.

The Impacts of VLN® Cigarettes

Advantages for Smokers

Numerous independent scientific studies, including those funded by the FDA and the National Institutes of Health, have demonstrated the benefits of using reduced nicotine content tobacco cigarettes like VLN®. These studies reveal the following advantages for smokers:

  1. Reduced Nicotine Exposure and Dependence: VLN® cigarettes help smokers reduce their nicotine exposure and dependence, enabling them to take control of their smoking habits.
  2. Decreased Cigarette Consumption: Smokers who switch to VLN® cigarettes tend to smoke fewer cigarettes per day, leading to a gradual reduction in overall cigarette consumption.
  3. Increased Smoke-Free Days: VLN® cigarettes have been shown to increase the number of smoke-free days, providing smokers with more opportunities to break free from nicotine addiction.
  4. Enhanced Quitting Attempts: Smokers using VLN® cigarettes are more likely to make double the number of attempts to quit smoking, without experiencing significant nicotine withdrawal or compensatory smoking behavior.

The positive impact of these findings on smokers and public health cannot be overstated. The FDA’s Comprehensive Plan for Tobacco and Nicotine Regulation estimates that implementing a nicotine cap, similar to the levels found in VLN® cigarettes, could help millions of smokers quit and prevent millions of smoking-related deaths in the future.

Licensing and Global Impact

22nd Century Group remains committed to licensing its reduced nicotine content technology and products to tobacco manufacturers worldwide. By enabling industry-wide compliance with the proposed FDA nicotine caps, 22nd Century Group aims to contribute to global public health efforts. Furthermore, international partnerships are being pursued to extend the availability of VLN® cigarettes beyond U.S. markets.


With VLN® cigarettes, smokers have a viable option to reduce their nicotine intake and minimize the harm caused by smoking. The recognition from the FDA and the positive results from scientific studies affirm the potential of VLN® cigarettes in harm reduction efforts. As 22nd Century Group continues to expand its licensing and global partnerships, the availability and impact of VLN® cigarettes are poised to grow, leading to a healthier future for smokers worldwide.

For more information about VLN® King and VLN® Menthol King cigarettes, please visit www.tryvln.com.

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Please consult with a healthcare professional before making any changes to your smoking habits.